Matt Gline is back with a new ‘vant’ company, after the Roivant Sciences CEO paid Bayer $14 million upfront for the rights to a phase 2-ready pulmonary hypertension drug. The asset in question, ...
Roivant Sciences ROIV announced the formation of a new Vant company with Pfizer PFE to advance the development of PF-06480605, a TL1A-directed antibody originally developed by Pfizer, for treating ...
Roivant Sciences Ltd.'s Vant model gives it risk-isolated development, monetization flexibility, and diversified optionality. ROIV's main value drivers are Immunovant, Priovant, Pulmovant, and ...
“I’m down, I’m tired, I’m broke, I wanted something more”. There goes Mattie Vant, frontman of indie rock band VANT, casually summing up 21st century life in 10 words. It’s something they do with ease ...